Rob Russo, The Economist's Canada correspondent, reveals the internal party conflicts leading to Justin Trudeau's resignation and the implications for future Canadian elections. Sophie Pedder, Paris bureau chief, reflects on the legacy of the Charlie Hebdo attacks, emphasizing the publication's commitment to satire despite ongoing threats. The discussion also highlights AI's transformative potential in the pharmaceutical industry, focusing on how it could reshape drug development by 2025, amidst challenges and optimism for future innovations.
Justin Trudeau's resignation reflects internal party strife and declining public support stemming from unfulfilled promises and economic disconnection.
Artificial intelligence is transforming the pharmaceutical industry by expediting drug development processes, significantly reducing time and costs involved.
Deep dives
The Significance of Site Selection for Expansion
Site selection is essential for businesses aiming to expand operations in the U.S., as it can significantly influence their success. Companies are advised to prioritize states with an educated workforce, robust infrastructure, and favorable tax conditions, with North Carolina often standing out as an optimal choice. This state boasts shovel-ready sites that can facilitate swift entry into markets, both domestically and internationally. Utilizing resources like edpnc.com can provide businesses with the critical information and connections needed for effective site selection.
Impact of AI on Drug Development
Artificial intelligence is poised to revolutionize the pharmaceutical industry, particularly in speeding up the drug development process. Currently, developing a new drug can take about ten years and costs over $2 billion, but AI technologies like DeepMind's AlphaFold are making significant advances by accurately predicting molecular structures. AI can streamline early research phases, reducing timeframes and costs considerably; for instance, companies like InSilico have achieved preclinical phases in 18 months and at a mere $2.7 million. Despite the complexities of human trials remaining a challenge, the integration of AI is expected to lead to smarter decision-making in drug development.
Justin Trudeau's Political Downfall
Justin Trudeau's resignation as Canada’s prime minister illustrates the significant loss of support he experienced over his decade-long leadership. Internal party conflicts and his inability to connect with voters on key issues, especially economic ones, have contributed to his declining popularity among Canadians, with polls showing about 80% advocating for his exit. Trudeau's failure to fulfill key promises, such as electoral reform, exacerbated his loss of public trust as priorities shifted towards pressing matters like housing costs and inflation. As the Liberal Party gears up for an impending leadership selection, the challenges of rebuilding public confidence remain daunting amidst a landscape shifted toward conservative ideologies.
In the end Justin Trudeau could not resist the internal pressure. We ask why the liberal standard-bearer got pushed out, and what comes next. Ten years after terrorists raided the offices of Charlie Hebdo, a satirical French newspaper, our correspondent speaks with its unbowed editor (10:10). And our series The World Ahead examines the nexus of AI and the pharmaceutical industry (19:08).